Related Experiment Video
Updated: Apr 16, 2026
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Novel targets in pancreatic cancer research
Geoffrey Kozak1, Fernando F Blanco2, Jonathan R Brody1
1Department of Surgery, Jefferson Center for Pancreatic, Biliary and Related Cancers, Thomas Jefferson University, Philadelphia, PA.
Abstract:
The initiation and progression of pancreatic ductal adenocarcinoma (PDA) occurs as a result of molecular alterations that typically result in fluctuations of transcription, protein expression, and ultimately dysregulated signaling pathways. For example, PDA is driven by key activating, gain-of-function mutations in proto-oncogenes (eg, K-Ras) along with loss of function of tumor suppressor genes (eg, p16, SMAD4). With the advent of whole-exome sequencing of PDA genomes, several key genetic alterations have been identified as drivers of PDA. While these findings have led to groundbreaking discoveries in the etiology of PDA, they have failed to provide feasible, targetable therapeutic approaches. Additionally, recent advances in PDA research have uncovered the role of the tumor microenvironment (the non-epithelial tumor cells) in PDA progression by promoting potent, acute changes in gene expression. Herein, this chapter is aimed at discussing the key genetic and non-genetic mechanisms responsible for PDA initiation and progression. Thus based on these mechanisms, we will put forth investigated and novel therapeutic targets in PDA.
Insights
Pancreatic ductal adenocarcinoma (PDA) arises from genetic mutations and tumor microenvironment changes. This review explores these mechanisms to identify novel therapeutic targets for PDA.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Pancreatic ductal adenocarcinoma (PDA) initiation and progression involve molecular alterations affecting gene expression and signaling pathways.
- Key drivers include oncogene mutations (e.g., K-Ras) and tumor suppressor gene inactivation (e.g., p16, SMAD4).
- The tumor microenvironment significantly influences PDA progression through gene expression modulation.
Purpose of the Study:
- To discuss the critical genetic and non-genetic mechanisms underlying PDA initiation and progression.
- To identify and propose investigated and novel therapeutic targets based on these mechanisms.
Main Methods:
- Review of existing literature on PDA genetics and molecular biology.
- Analysis of whole-exome sequencing data to identify genetic drivers.
- Exploration of the role of the tumor microenvironment in PDA pathogenesis.
Main Results:
- Identification of key genetic alterations (e.g., K-Ras mutations, tumor suppressor gene loss) driving PDA.
- Recognition of the tumor microenvironment's role in PDA progression via gene expression changes.
- Gaps in current therapeutic strategies despite genetic discoveries.
Conclusions:
- Understanding PDA's complex genetic and non-genetic mechanisms is crucial for therapeutic development.
- Targeting both genetic drivers and the tumor microenvironment holds promise for PDA treatment.
- Further research is needed to translate these findings into effective, targetable therapies.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies